abp688
Small moleculeexperimentalImaging agent
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
1
Earliest trial started Aug 1, 2008 (NCT01528241)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Metabotropic glutamate receptor 5Radiopharmaceutical
GRM5 radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 11-carbon
Oral
No
Parenteral
No
Topical
No
Also known as
- 3-(6-methylpyridin-2-ylethynyl)-cyclohex-2-enone-o-11c-methyl-oxime
- 3-(6-methylpyridin-2-ylethynyl)cyclohex-2-enone-o-methyloxime
- abp688
- abp688
- abp688
- abp 688
- abp-688
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07076342 | Phase 4 | Aug 1, 2025 | National Institute of Mental Health (NIMH), National Institutes of Health (NIH), Stony Brook University |
| NCT01528241 | Phase 1 | Aug 1, 2008 | Novartis |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Mental Health (NIMH) | Government | 1 | 0 | 1 | 2025 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2025 |
| Novartis | For profit | 1 | 1 | 1 | 2008 |
| Stony Brook University | Academic/Hospital | 1 | 1 | 1 | 2025 |
4 organizations
Page 1 / 1